These findings highlight CES1 as a potential therapeutic target for CNS relapse, underscoring its role in metabolic regulation and modulation of the tumor microenvironment, as well as the need for the development of novel CES1 inhibitors with improved bioavailability. This evidence concerns the gene CES1 and neoplasm.